Amylyx Pharmaceuticals Files 8-K Report
Ticker: AMLX · Form: 8-K · Filed: Dec 30, 2024 · CIK: 1658551
Sentiment: neutral
Topics: sec-filing, regulatory, reporting
Related Tickers: AMYX
TL;DR
AMYX filed a routine 8-K, no major news.
AI Summary
On December 30, 2024, Amylyx Pharmaceuticals, Inc. filed an 8-K report. The filing indicates it is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The report does not detail specific events but serves as a notification of ongoing reporting obligations.
Why It Matters
This filing confirms Amylyx Pharmaceuticals is meeting its regulatory reporting requirements with the SEC, which is standard for publicly traded companies.
Risk Assessment
Risk Level: low — This is a standard regulatory filing confirming ongoing reporting obligations and does not contain new material information.
Key Numbers
- 001-41199 — SEC File Number (Identifies the company's filings with the SEC.)
- 46-4600503 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Amylyx Pharmaceuticals, Inc. (company) — Registrant
- December 30, 2024 (date) — Date of Report
- 001-41199 (other) — Commission File Number
- 46-4600503 (other) — IRS Employer Identification No.
- 43 Thorndike St., Cambridge, MA 02141 (address) — Principal executive offices
FAQ
What is the purpose of this 8-K filing?
This 8-K filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, indicating the company is fulfilling its ongoing reporting obligations.
What is the exact date of the earliest event reported?
The date of the earliest event reported is December 30, 2024.
What is Amylyx Pharmaceuticals, Inc.'s Commission File Number?
Amylyx Pharmaceuticals, Inc.'s Commission File Number is 001-41199.
Where are Amylyx Pharmaceuticals, Inc.'s principal executive offices located?
Amylyx Pharmaceuticals, Inc.'s principal executive offices are located at 43 Thorndike St., Cambridge, MA 02141.
Does this filing disclose any new material events or financial information?
Based on the provided text, this filing appears to be a standard confirmation of reporting status and does not detail specific new material events or financial information.
Filing Stats: 882 words · 4 min read · ~3 pages · Grade level 15 · Accepted 2024-12-30 07:50:30
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share AMLX Nasdaq Glo
- $50 million — Gubra is eligible to receive more than $50 million in success-based development and commer
Filing Documents
- d920512d8k.htm (8-K) — 26KB
- 0001193125-24-286212.txt ( ) — 142KB
- amlx-20241230.xsd (EX-101.SCH) — 3KB
- amlx-20241230_lab.xml (EX-101.LAB) — 17KB
- amlx-20241230_pre.xml (EX-101.PRE) — 11KB
- d920512d8k_htm.xml (XML) — 3KB
Forward-Looking Statements
Forward-Looking Statements
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. AMYLYX PHARMACEUTICALS, INC. Date: December 30, 2024 By: /s/ James M. Frates James M. Frates Chief Financial Officer